3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
5
Phase 2
5
Phase 3
2
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Glioblastoma
12
Astrocytoma
11
Glioma
10
Brain Neoplasms
9
Gliosarcoma
7
Oligodendroglioma
6
Central Nervous System Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Carcinoma, Non-Small-Cell Lung
5
Rectal Neoplasms
4
Breast Neoplasms
4
Meningioma
3
Esophageal Neoplasms
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Sarcoma
2
Salivary Gland Neoplasms
2
Recurrence
2
Pinealoma
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Medulloblastoma
2
Craniopharyngioma
2
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Interventions
Paclitaxel
68
Carboplatin
64
pembrolizumab
32
Cyclophosphamide
31
Bevacizumab
27
liposomal doxorubicin
24
Cisplatin
24
Topotecan
21
Gemcitabine
21
olaparib
18
fludarabine
16
Taxes
16
Docetaxel
15
Nivolumab
14
Doxorubicin
14
niraparib
13
veliparib
12
Albumin-Bound Paclitaxel
11
aldesleukin
9
Filgrastim
9
fludarabine phosphate
8
durvalumab
8
Oxaliplatin
8
Fluorouracil
8
Drug Therapy
8
sargramostim
7
Peripheral Blood Stem Cell Transplantation
7
Magnetic Resonance Spectroscopy
7
Leucovorin
7
talazoparib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Ovarian Neoplasms
×
Surgical Procedures, Operative
×
Clear all
NCT06281860
2024-02-28
PITHAC
Centre Hospitalier Universitaire Vaudois
Phase 1
Unknown
39 enrolled